No Multiple Payments Sample Clauses
The No Multiple Payments clause ensures that a party is not required to make duplicate payments for the same obligation or liability under a contract. In practice, this means that if a party has already fulfilled a payment obligation in one section of the agreement, they cannot be asked to pay again for the same issue elsewhere in the contract. This clause prevents double recovery and ensures fairness by clarifying that each obligation is satisfied by a single payment, thereby avoiding disputes over overlapping or redundant payment demands.
No Multiple Payments. Settlement of the Phantom Units shall not occur under more than one provision of this Agreement.
No Multiple Payments. Only a single royalty shall be due and payable by Licensee under this Agreement with respect to a Licensed Product or Licensed Service regardless of whether the Licensed Product or Licensed Service is covered by more than one Valid Claim.
No Multiple Payments. Settlement of the Restricted Units shall not occur under more than one provision of this Agreement.
No Multiple Payments. In no event shall any of the milestone payments described in each of Articles 4.2
(a) through (i) be paid more than once, irrespective of the number of Licensed Products (or respective Indications for which they are approved) marketed or sold by or on behalf of ALGORX, its Affiliates or their sublicensees.
No Multiple Payments. Notwithstanding any provision of this Agreement to the contrary:
(a) if any Milestone Product is a “Licensed Product” as such term is defined in the S1P Agreement, then no milestone payments with respect to such Milestone Product will be due by Company under this Agreement, and only the applicable milestone payment obligations under the S1P Agreement will apply;
(b) if any Partner Product is a “Licensed Product” as such term is defined in the S1P Agreement, then no payments with respect to such Partner Product will be due by Company under this Agreement, and only the applicable payment obligations under the S1P Agreement will apply to such Partner Product; and
(c) if any item of License Revenue constitutes “Sublicense Revenues” as such term is defined in the S1P Agreement, then no payments with respect to such item of License Revenue will be due by Company under this Agreement, and only the applicable payment obligations under the S1P Agreement will apply to such item of License Revenue.
No Multiple Payments. For the avoidance of doubt no milestone payment shall be made more than once, irrespective of the number of Products (including combinations with other products) or the number of indications that have achieved the milestone or the number of countries in which such milestone has been achieved.
No Multiple Payments. For the avoidance of doubt only one Option Exercise Fee payment shall be made for each respective Lead Series (including potential back up compounds) and only if Bayer exercised the Option for such respective Lead Series.
No Multiple Payments. For the avoidance of doubt only one Option Exercise Fee payment shall be made for each respective Development Candidate (including potential back up compounds) and only if Bayer exercised the Option for such respective Development Candidate.
No Multiple Payments. For purposes of clarity, in the event that any milestone event set forth in Section 6.4.1 and/or Section 6.4.2 is achieved by a Sublicensee, X4 shall be obligated to pay to Genzyme the applicable milestone payment contemplated by Section 6.4.1 or Section 6.4.2, as the case may be, but shall not be obligated to pay Genzyme the Sublicense Percentage of any such milestone payment received by X4 from such Sublicensee.
No Multiple Payments. For payments pursuant to Section 3.2, only one payment shall be paid for each Licensed Product sold, regardless of the number of Licensed Patents or claims thereof that cover such Licensed Product. Additionally, in the event Licensee has paid Baxter a sales-based contingent payment on the Net Sales of a unit of Licensed Product pursuant to Section 2.4 of the Asset Purchase Agreement, Licensee shall not pay Baxter a royalty, pursuant to Section 3.2 of this Agreement, on the Net Sales of that unit of Licensed Product.